NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

Alamar Biosciences, Inc. (ALMR) Stock Analysis

Alamar Biosciences, Inc. (ALMR) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ALMR

$31.45

+$3.29 (+11.68%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALMR with… →

ALMR Key Statistics

As of Oct 21, 2026
Trading
Open
$28.39
Previous Close
$28.16
Day's Range
28.17–31.51
52-Week Range
18.85–39.61
Volume
1.14M
Valuation
Market Cap
$2.18B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
21.73
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.20
Financials (FY)
Revenue (FY)
$74.21M+195.17%
Net Income (FY)
−$29.82M
Profit marginThe share of revenue left as profit after all costs and taxes.
−49.45%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
69.39M
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
476.25K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Alamar Biosciences, Inc. (ALMR) has a market capitalization of $2.18B.

In fiscal 2025, ALMR reported revenue of $74.21M.

ALMR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$74.21M−$29.82M−40.2%
2024$25.14M−$47.07M−187.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$74.21M$41.71M−$31.33M−$29.82M−40.2%
2024$25.14M$8.61M−$49.57M−$47.07M−187.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ALMR Valuation vs Medical Devices Median

Median of 145 stocks
MetricALMRMedical Devices medianvs median
P/S ratio21.732.538.6x the median
Profit margin−49.45%−14.78%34.7 pts below

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Alamar Biosciences, Inc. (ALMR) carries a market capitalisation of $2.18B. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 286.

The 52-week range on file runs from $18.85 to $39.61. The most recent close on file for ALMR is $31.45, dated October 21, 2026. That is +$3.29 (+11.68%) against the previous close. The latest close sits 66.84% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $74.21M. Against the prior fiscal year total of $25.14M, that is a change of +195.17%. The same year closed with a net loss of $29.82M. The reported profit margin is −49.45%. That is 34.7 percentage points below the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to −1.2.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 21.73 times revenue. On price-to-sales that is 8.6 times the Medical Devices median of 2.53. 145 Medical Devices companies report these metrics, and the medians quoted come from that group.

The stored price history starts on April 17, 2026, and the total return since then is +42.95%.

Growth & Income

No dividend is on file for ALMR.

2026 is still running; the total return is +42.95% year to date.

Peer Comparison

Alamar Biosciences, Inc. (ALMR) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Alamar Biosciences, Inc. ALMR $2.18B —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. Alamar Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Alamar Biosciences, Inc.

Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California.

Visit website →